Supraventricular Tachycardia Treatment Market By Treatment Type (Acute Self-Administered Prescription Therapies, Hospital-Administered Acute Drugs, Chronic Oral Pharmacotherapy, Catheter Ablation, Electrical Cardioversion); By Application (Paroxysmal Supraventricular Tachycardia, Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Re-entrant Tachycardia, Wolff-Parkinson-White Syndrome-Associated SVT, Focal Atrial Tachycardia, Recurrent Symptomatic SVT, Pediatric Supraventricular Tachycardia); By End User (Hospitals and Emergency Departments, Cardiology Clinics, Electrophysiology Centres, Ambulatory Surgical Centres, Retail Pharmacies, Specialty Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Supraventricular Tachycardia Treatment Market: Outpatient Episode Control Redirects Revenue from Emergency Care to Prescription and Ablation Channels

The Global Supraventricular Tachycardia Treatment Market was valued at USD 4.99 billion in 2025 and is projected to reach USD 7.55 billion by 2032, growing at a CAGR of 6.1%, according to Strategic Market Research.

 

Frequent emergency visits are increasing payer interest in treatments that can terminate supraventricular tachycardia episodes outside hospital settings. The December 2025 FDA approval of Cardamyst opened a new outpatient prescription pathway, while catheter ablation continues to generate the highest treatment value per patient. Suppliers are better positioned when they can reduce hospital use, secure formulary access, maintain dependable acute-treatment supply, and support electrophysiology centres with procedure-related products and services.

 

The clearest public evidence relates to paroxysmal supraventricular tachycardia, or PSVT, which accounts for a large share of documented emergency visits, prescriptions, and ablation activity across the wider SVT treatment market. Available data cover diagnosed patients, hospital encounters, payer spending, procedure costs, reimbursement decisions, regulatory approvals, early prescription use, and supply constraints.

 

Recurring Hospital Use Raises the Value of Earlier Episode Control

A U.S. claims analysis projected approximately 1.26 million prevalent SVT patients and 188,981 incident patients annually based on the 2018 population. The estimate excluded patients with atrial fibrillation and atrial flutter, making it more conservative than broader calculations that place the potential population above two million.

Treatment revenue depends more on episode frequency and clinical severity than on the total patient population. Patients with occasional self-terminating events may require little intervention, while recurrent or prolonged episodes often lead to emergency assessment, diagnostic testing, specialist care, observation, hospital admission, medication, or catheter ablation. Spending is therefore concentrated among patients with repeated symptoms, prior emergency visits, or persistent treatment needs.

U.S. emergency-department visits with PSVT as the primary diagnosis increased from 129,219 in 2016 to 139,992 in 2019. A broader coding definition that included PSVT in additional diagnostic positions identified 259,916 visits in 2019. Coding differences explain the wide range, but both estimates confirm a substantial flow of patients into institutional treatment.

Hospital escalation creates the largest avoidable cost. In 2019, 24.2% of primary-diagnosis PSVT emergency visits resulted in inpatient admission, while another 10.1% involved observation stays. Women represented 59.3% of visits, and adults younger than 65 accounted for 62.6%. Commercial insurers, employers, pharmacy benefit managers, and managed-care organizations therefore carry a large share of the cost generated by unpredictable episodes among working-age adults.

Insurer-paid expenditure rises sharply after diagnosis. Mean annual spending among patients younger than 65 increased from USD 9,028 before diagnosis to USD 29,867 during the following year. Spending among patients aged 65 and older rose from USD 10,867 to USD 20,143. PSVT-specific services accounted for 43% of the increase in the younger group and 33% among older patients.

Emergency transport, cardiac testing, physician assessment, observation, and hospital admission account for most of the acute-care cost, rather than the medication itself. Outpatient therapies may justify premium reimbursement if they reduce these services, but payers will require evidence that treatment prevents emergency use rather than simply adding expense.

 

Cardamyst Establishes an Outpatient Prescription Segment

The FDA approved Cardamyst, or etripamil nasal spray, on December 12, 2025, for converting acute symptomatic PSVT episodes to sinus rhythm in adults. U.S. retail availability began in January 2026, followed by a national promotional launch in February. Cardiologists can now prescribe an acute treatment before the patient experiences another episode instead of waiting for an emergency presentation.

The RAPID study provided the clinical basis for approval. Among patients who treated a confirmed episode, 64% of those receiving Cardamyst converted to sinus rhythm within 30 minutes, compared with 31% receiving placebo. Median conversion time was approximately 17 minutes with Cardamyst and 54 minutes with placebo.

Faster conversion supports the product’s economic proposition because patients can use it outside a monitored hospital setting. The approved population remains narrower than the total SVT base. Cardamyst is indicated for adults with acute symptomatic PSVT, while label restrictions exclude some patients with heart failure, conduction abnormalities, pre-excitation syndromes, and other cardiac conditions. Market estimates based on total SVT prevalence would therefore overstate the practical prescription population.

Initial launch data indicate interest across a relatively broad prescriber base. Through April 2026, Milestone Pharmaceuticals reported approximately 600 filled prescriptions covering 560 patients and around 400 unique prescribers. Prescription volume remained modest, but the number of participating prescribers suggests that early adoption was not limited to a small number of electrophysiology centres.

The outpatient segment will depend on repeat use. Public data do not yet show refill rates, episode frequency, annual use per patient, or prescription abandonment. Patients with recurrent episodes may drive repeat prescriptions, whereas those with occasional events may retain a prescription for extended periods without replacement.

Milestone deployed a 60-person national sales force targeting cardiologists, electrophysiologists, and advanced-practice providers. This focused prescriber base limits the need for broad primary-care promotion, but uptake still depends on reaching practices that manage recurrent episodes, medically treated patients, or follow-up after emergency care.

 

Formulary Access Determines Prescription Conversion

FDA approval opened the treatment category, but payer coverage determines whether prescriptions convert into revenue. Express Scripts added Cardamyst to its commercial national formularies effective March 27, 2026. By the end of April, Milestone reported coverage for more than 25% of commercially insured U.S. lives.

Commercial coverage is particularly relevant because adults younger than 65 account for most primary-diagnosis PSVT emergency visits. Health plans can compare the cost of an outpatient prescription with emergency visits, observation stays, admissions, and work disruption linked to unpredictable episodes.

Coverage is unlikely to remain unrestricted across the entire diagnosed population. Payers may review episode frequency, previous emergency utilization, contraindications, ablation status, and the probability that outpatient treatment will prevent institutional care. Prior authorization could concentrate access among recurrent or high-cost patients.

Milestone stated a wholesale acquisition cost of USD 1,649 per prescription and estimated net sales of USD 500 to USD 1,000 per prescription. Rebates, payer contracts, distribution fees, copay assistance, and patient-support programs account for part of the difference between list and expected net value. Revenue calculations based only on wholesale acquisition cost would materially overstate manufacturer sales.

The company reported USD 238,000 in net product revenue for the quarter ended March 31, 2026, compared with USD 15.8 million in commercial expense. The period covered only the opening weeks of launch and should not be annualized. Commercial spending reflects the cost of physician education, payer contracting, benefit verification, retail distribution, and patient support required to establish a new prescription category.

Cardamyst competes against more than another branded drug. Physicians and patients can continue using inexpensive chronic medication, off-label pill-in-pocket approaches, emergency treatment, watchful waiting, or catheter ablation. Milestone must prove that outpatient treatment reduces hospital dependence rather than simply adding another option.

The planned RESET-PSVT Phase 4 registry with Duke Clinical Research Institute is expected to collect real-world evidence on repeat administration, emergency avoidance, safety, and treatment satisfaction. Such evidence could support broader formulary access, although no registry results were available as of July 14, 2026.

 

Catheter Ablation Retains the Highest Per-Patient Revenue

Catheter ablation remains the premium segment of SVT treatment. Hospitals, electrophysiologists, mapping-system suppliers, catheter manufacturers, and service providers earn substantially more revenue per treated patient than suppliers of routine oral medication or generic emergency drugs.

A 2024 U.S. claims study found first-year expenditure of USD 48,004 among ablation patients compared with USD 17,560 among matched patients receiving medical therapy. Mean expenditure for the ablation procedure itself was USD 32,057. In years two and three, overall spending declined to levels similar to the medical-therapy group, while fewer ablation patients required beta blockers, calcium-channel blockers, or antiarrhythmic prescriptions.

High upfront expenditure supports procedure and device revenue but can slow payer authorization. The study did not find that total costs fell below medical therapy during the following two years. Insurers may therefore continue requiring specialist documentation and medical-necessity review rather than treating ablation as an automatic cost-saving intervention.

Only 13% of newly diagnosed patients younger than 65 and 3% of those aged 65 or older underwent ablation within one year in a separate claims analysis. Referral delays, limited procedure capacity, insurance authorization, clinical suitability, and patient reluctance keep a large population within medication and acute-care pathways.

Outpatient episode treatment is more likely to complement ablation than replace it. Patients with frequent or severe episodes may still choose a procedure. Patients waiting for ablation can use an acute prescription as a bridge, while those unwilling or unable to undergo an intervention provide a stronger base for continuing prescription demand.

Established cardiovascular device companies remain difficult to displace because hospitals already use their mapping systems, catheters, training, and service networks. Smaller hardware-only suppliers often struggle to gain adoption in established electrophysiology departments.

 

Treatment-Type Segments Follow Different Revenue Models

Catheter ablation captures the highest value within the treatment-type segmentation because each procedure generates hospital reimbursement, specialist fees, mapping-system use, ablation-catheter demand, and disposable sales. Its growth remains tied to referral rates, procedural capacity, and payer authorization.

Acute self-administered prescription therapies represent the newest treatment segment. Cardamyst created a channel that can capture patients before they reach an emergency department. Revenue will depend on formulary coverage, repeat episodes, refill behaviour, and proof of reduced institutional care.

Hospital-administered acute drugs continue to generate dependable demand because symptomatic episodes often require immediate intervention. Generic pricing limits margins, while product shortages make supply reliability an important competitive factor.

Chronic oral pharmacotherapy serves the large population that has not undergone ablation or does not qualify for an acute self-administered product. The segment benefits from recurring use but remains price-sensitive because many medicines are generic. Electrical cardioversion accounts for a smaller institutional segment and is generally reserved for cases requiring urgent rhythm restoration when other approaches are unsuitable or unsuccessful.

 

PSVT and Recurrent Symptomatic Cases Generate the Most Measurable Demand

Paroxysmal supraventricular tachycardia accounts for the clearest treatment demand within the application segmentation because recurrent episodes generate prescriptions, emergency visits, observation stays, and ablation referrals. The Cardamyst approval also directly expands the commercial focus on acute symptomatic PSVT.

Atrioventricular nodal re-entrant tachycardia and atrioventricular re-entrant tachycardia support substantial ablation activity because electrophysiology procedures can target the abnormal pathway involved. Wolff-Parkinson-White-associated SVT often moves patients toward specialist assessment and earlier procedural consideration because of the accessory pathway and associated rhythm risk.

Focal atrial tachycardia represents a smaller and more complex treatment group that may require repeated medication adjustment or ablation. Recurrent symptomatic SVT provides the strongest base for acute outpatient treatment because these patients have the greatest incentive to avoid repeated hospital visits.

Pediatric SVT remains a specialist-led niche. Demand is concentrated in children’s hospitals, pediatric cardiology services, and electrophysiology centres that can balance medication against age, weight, episode burden, and the timing of ablation.

 

Care Settings Divide Volume from Per-Patient Value

Hospitals and emergency departments account for the largest treatment volume because acute episodes often require monitored medication, cardiac testing, observation, or admission. Demand is concentrated in hospital injectables, diagnostics, and urgent interventions.

Electrophysiology centres capture the highest revenue per patient through ablation procedures, mapping systems, catheters, and follow-up services. Cardiology clinics are becoming more important as acute outpatient therapies move treatment initiation into specialist offices, where physicians identify suitable patients before the next episode.

Ambulatory surgical centres can handle more procedures where reimbursement and local rules permit electrophysiology outside hospitals. Retail and specialty pharmacies distribute Cardamyst and other prescriptions, but uptake depends on formulary access, benefit verification, copay support, and prior authorization.

 

Regional Growth Depends on Reimbursement and Procedure Capacity

North America leads the transition toward outpatient episode treatment. The United States combines a large claims-defined population, measurable emergency utilization, high ablation expenditure, FDA approval, retail distribution, specialist promotion, and commercial insurance coverage. Fragmented payer access remains the main limitation on prescription growth.

Europe depends more heavily on public reimbursement, commissioned electrophysiology capacity, and country-level pricing decisions. The European Medicines Agency accepted the etripamil marketing-authorization application for review, with a company-expected decision in the first half of 2027. Any approval would still require national reimbursement and pricing decisions before broad commercial access.

NHS England previously estimated that more than 200,000 people in the United Kingdom were affected by SVT and cited a service benchmark of 100 to 150 SVT ablations per million population. Procedure revenue in the United Kingdom therefore depends on funded electrophysiology capacity as much as patient prevalence.

Australia recorded 3,270 reimbursed non-atrial-fibrillation SVT ablation services in the cited 2018 government data. A later reimbursement assessment cited an A$6,399 bundled amount for the relevant ablation-device group. Public listing decisions directly influence hospital purchasing, device pricing, and supplier access.

Greater China represents a longer-term prescription opportunity. The Chinese application for etripamil was accepted in January 2025, and Everest Medicines acquired Greater China development and commercialization rights in March 2026. Approval, hospital access, pricing, and reimbursement remain unresolved.

Latin America and the Middle East and Africa remain more dependent on hospital drugs and major urban cardiac centres. Uneven insurance coverage, specialist availability, and procedure capacity limit access to premium outpatient therapies and ablation outside higher-income markets.

 

Suppliers with Evidence and Access Will Capture the Revenue Shift

Milestone Pharmaceuticals currently defines the branded outpatient PSVT segment in the United States. Prescription growth, repeat use, payer coverage, and evidence of fewer emergency encounters will determine whether the category reaches scale.

Cardiovascular device suppliers generate revenue from procedure-linked disposables, installed mapping systems, service contracts, and established physician use. Generic drug manufacturers compete for hospital contracts on price, product availability, and wholesaler performance. In outpatient care, PBMs and insurers increasingly determine access, with Express Scripts’ formulary decision showing how payer contracting can accelerate or restrict uptake.

Near-term revenue will come mainly from diagnosed adults with disruptive episodes who have not undergone ablation. Outpatient prescription growth will depend on treating patients currently managed in emergency departments or with existing medicines without materially increasing pharmacy costs. Catheter ablation will remain the highest-value hospital procedure, while acute-care drugs will remain necessary but constrained by generic pricing and supply risk. Share gains will favour suppliers with economic evidence, specialist access, broad reimbursement and reliable manufacturing.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 4.99 Billion
Revenue Forecast in 2032	USD 7.55 Billion
Overall Growth Rate	CAGR of 6.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Application, By End User, By Geography
By Treatment Type	Acute Self-Administered Prescription Therapies, Hospital-Administered Acute Drugs, Chronic Oral Pharmacotherapy, Catheter Ablation, Electrical Cardioversion
By Application	Paroxysmal Supraventricular Tachycardia, Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Re-entrant Tachycardia, Wolff-Parkinson-White Syndrome-Associated SVT, Focal Atrial Tachycardia, Recurrent Symptomatic SVT, Pediatric Supraventricular Tachycardia
By End User	Hospitals and Emergency Departments, Cardiology Clinics, Electrophysiology Centres, Ambulatory Surgical Centres, Retail Pharmacies, Specialty Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, China, Japan, India, Australia, South Korea, Brazil, Argentina, Saudi Arabia, UAE, South Africa
Market Drivers	Rising diagnosis of recurrent symptomatic SVT, wider access to electrophysiology services, growing use of catheter ablation for rhythm correction, stronger emergency care pathways, and increasing availability of acute prescription-based therapies
Customization Option	Available upon request